Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harman Dhatt

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Managed Care & Specialty Pharmacy|June 5, 2023
It is time for a new comprehensive medication review quality measureMelissa Castora-Binkley, Lisa Hines, Shannon Vaffis, et al.
Rheumatology and Therapy|September 23, 2025
Real-World Assessment of Systemic Disease Activity in Seropositive and Seronegative Patients with Sjögren's Disease and Association with Patient-Reported OutcomesJacques-Eric Gottenberg, Raphaele Seror, Nicola Massey, et al.
Lancet (London, England)|November 24, 2025
Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trialGhaith Noaiseh, Kathy L Sivils, Kim Campbell, et al.
Expert Review of Clinical Immunology|February 18, 2026
Nipocalimab for the treatment of moderate-to-severe Sjögren's disease: a plain language summary of the DAHLIAS studyGhaith Noaiseh, Kathy L Sivils, Kim Campbell, et al.
Medicine|December 20, 2014
Economic evaluation of urgent-start peritoneal dialysis versus urgent-start hemodialysis in the United StatesFrank Xiaoqing Liu, Arshia Ghaffari, Harman Dhatt, et al.
RMD Open|June 28, 2024
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA studyPeter C Taylor, Georg Schett, Tom Wj Huizinga, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Managed Care & Specialty Pharmacy|June 5, 2023
It is time for a new comprehensive medication review quality measureMelissa Castora-Binkley, Lisa Hines, Shannon Vaffis, et al.
Rheumatology and Therapy|September 23, 2025
Real-World Assessment of Systemic Disease Activity in Seropositive and Seronegative Patients with Sjögren's Disease and Association with Patient-Reported OutcomesJacques-Eric Gottenberg, Raphaele Seror, Nicola Massey, et al.
Lancet (London, England)|November 24, 2025
Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trialGhaith Noaiseh, Kathy L Sivils, Kim Campbell, et al.
Expert Review of Clinical Immunology|February 18, 2026
Nipocalimab for the treatment of moderate-to-severe Sjögren's disease: a plain language summary of the DAHLIAS studyGhaith Noaiseh, Kathy L Sivils, Kim Campbell, et al.
Medicine|December 20, 2014
Economic evaluation of urgent-start peritoneal dialysis versus urgent-start hemodialysis in the United StatesFrank Xiaoqing Liu, Arshia Ghaffari, Harman Dhatt, et al.
RMD Open|June 28, 2024
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA studyPeter C Taylor, Georg Schett, Tom Wj Huizinga, et al.
Pageof 2